Giuseppe Remuzzi

Summary

Affiliation: Istituto di Ricerche Farmacologiche Mario Negri
Country: Italy

Publications

  1. ncbi request reprint Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses
    Carlos Chiurchiu
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 16:S58-63. 2005
  2. doi request reprint The aggravating mechanisms of aldosterone on kidney fibrosis
    Giuseppe Remuzzi
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 19:1459-62. 2008
  3. ncbi request reprint Rare diseases: what's next?
    Giuseppe Remuzzi
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Laboratori Negri Bergamo, 24125 Bergamo, Italy
    Lancet 371:1978-9. 2008
  4. pmc Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT
    Salvatore De Cosmo
    Unit of Endocrinology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    Diabetes 58:2920-9. 2009
  5. pmc The role of renin angiotensin system inhibition in kidney repair
    Irene M van der Meer
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Fibrogenesis Tissue Repair 3:7. 2010
  6. ncbi request reprint Routine renin-angiotensin system blockade in renal transplantation?
    Giuseppe Remuzzi
    Department of Immunology and Clinic of Organ Transplantation, Ospedali Riuniti di Bergamo and Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Curr Opin Nephrol Hypertens 11:1-10. 2002
  7. ncbi request reprint Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study
    Giuseppe Remuzzi
    Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Am Soc Nephrol 17:S90-7. 2006
  8. ncbi request reprint Investigational drugs for diabetic nephropathy
    Monica Cortinovis
    Mario Negri Institute for Pharmacological Research, Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy
    Expert Opin Investig Drugs 17:1487-500. 2008
  9. doi request reprint Which antihypertensive drugs are the most nephroprotective and why?
    Paolo Cravedi
    Mario Negri Institute of Pharmacological Research, Parco Scientifico Tecnologico Kilometro Rosso, Department of Medicine and Transplantation, Via Stezzano, 87, Ospedali Riuniti, 24126 Bergamo, Italy
    Expert Opin Pharmacother 11:2651-63. 2010
  10. ncbi request reprint Independent clinical research in Europe
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Bergamo and Milan, Italy
    Lancet 364:1723-6. 2004

Detail Information

Publications121 found, 100 shown here

  1. ncbi request reprint Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses
    Carlos Chiurchiu
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 16:S58-63. 2005
    ..The meta-analyses, however, represent a valuable tool to evaluate the consistency and generalizability of trial results to larger cohorts of patients...
  2. doi request reprint The aggravating mechanisms of aldosterone on kidney fibrosis
    Giuseppe Remuzzi
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 19:1459-62. 2008
    ..Nevertheless, further studies in larger populations with longer follow-up are warranted to address more definitely the safety and renoprotective effect of aldosterone antagonism in chronic kidney disease patients...
  3. ncbi request reprint Rare diseases: what's next?
    Giuseppe Remuzzi
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Laboratori Negri Bergamo, 24125 Bergamo, Italy
    Lancet 371:1978-9. 2008
  4. pmc Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT
    Salvatore De Cosmo
    Unit of Endocrinology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    Diabetes 58:2920-9. 2009
    ..We prospectively evaluated the association between Pro12Ala polymorphism (rs1801282) and new-onset microalbuminuria...
  5. pmc The role of renin angiotensin system inhibition in kidney repair
    Irene M van der Meer
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Fibrogenesis Tissue Repair 3:7. 2010
    ..This is a desirable goal, considering the economic burden of chronic kidney diseases and their effect on morbidity and mortality...
  6. ncbi request reprint Routine renin-angiotensin system blockade in renal transplantation?
    Giuseppe Remuzzi
    Department of Immunology and Clinic of Organ Transplantation, Ospedali Riuniti di Bergamo and Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Curr Opin Nephrol Hypertens 11:1-10. 2002
    ....
  7. ncbi request reprint Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study
    Giuseppe Remuzzi
    Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Am Soc Nephrol 17:S90-7. 2006
    ..The apparent advantage of ACE inhibitors over other agents includes a protective effect on the kidney against the development of microalbuminuria, which is a major risk factor for cardiovascular events and death in this population...
  8. ncbi request reprint Investigational drugs for diabetic nephropathy
    Monica Cortinovis
    Mario Negri Institute for Pharmacological Research, Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy
    Expert Opin Investig Drugs 17:1487-500. 2008
    ..Diabetic nephropathy is one of the main causes of end-stage renal disease (ESRD) and is associated with elevated cardiovascular morbidity and mortality...
  9. doi request reprint Which antihypertensive drugs are the most nephroprotective and why?
    Paolo Cravedi
    Mario Negri Institute of Pharmacological Research, Parco Scientifico Tecnologico Kilometro Rosso, Department of Medicine and Transplantation, Via Stezzano, 87, Ospedali Riuniti, 24126 Bergamo, Italy
    Expert Opin Pharmacother 11:2651-63. 2010
    ..Choice of antihypertensive strategies with highest nephroprotective effect is crucial to prevent or reverse progression to end stage renal disease (ESRD)...
  10. ncbi request reprint Independent clinical research in Europe
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Bergamo and Milan, Italy
    Lancet 364:1723-6. 2004
  11. ncbi request reprint Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation
    Giuseppe Remuzzi
    Department of Medicine and Transplantation, Ospedali Riuniti, Bergamo, Italy
    Am J Transplant 5:1146-50. 2005
    ..This case indicates that more fundamental research is needed before combined liver and kidney transplant is considered an option for children with HF-1-associated HUS...
  12. doi request reprint Why rare diseases?
    Giuseppe Remuzzi
    Laboratori Negri Bergamo, Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Ranica BG, Italy
    Ann Ist Super Sanita 47:94-7. 2011
    ..In other words, studying a rare condition may enlighten the path to other discoveries and to break the boundaries between disciplines and specialities to provide solutions for the sake of the patients...
  13. ncbi request reprint Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Ann Intern Med 136:604-15. 2002
    ..A multimodal approach that centers on reducing or removing all risk factors associated with the progression of renal disease may decrease the time to remission of the disease for most patients with proteinuric nephropathies...
  14. pmc Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Clin Invest 116:288-96. 2006
    ..This review describes recent advances in our understanding of the mechanisms and mediators underlying renal tissue repair ultimately responsible for regression of renal injury...
  15. ncbi request reprint Combined kidney and liver transplantation for familial haemolytic uraemic syndrome
    Giuseppe Remuzzi
    Ospedali Riuniti, Bergamo, Italy
    Lancet 359:1671-2. 2002
    ..The operation was successful, and at discharge, the child had healthy kidney and liver function, with no sign of haemolysis...
  16. ncbi request reprint Overview of randomised trials of ACE inhibitors
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research and Unit of Nephrology and Dialysis, Ospedali Riuniti, Bergamo 24125, Italy
    Lancet 368:555-6. 2006
  17. ncbi request reprint New therapeutics that antagonize endothelin: promises and frustrations
    Giuseppe Remuzzi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Nat Rev Drug Discov 1:986-1001. 2002
    ..Here, we discuss preclinical and clinical results with endothelin antagonists, and consider possible approaches to fully realizing the potential of endothelin antagonism...
  18. ncbi request reprint Rituximab for idiopathic membranous nephropathy
    Giuseppe Remuzzi
    Ospedali Riuniti Di Bergam, Unit of Nephrology and Dialysis, Aldo and Cele Daccò Clinical Research Centre for Diseases, Mario Negri Institute for Parmacological Research, Via Gavazzeni 1124125, Bergamo, Italy
    Lancet 360:923-4. 2002
    ..CD20 B lymphocytes fell below normal ranges up to study end. The short-term risk-benefit profile of rituximab seems more favourable to that of any other immunosuppressive drug used to treat idiopathic membranous nephropathy...
  19. ncbi request reprint V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction
    Norberto Perico
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 76:960-7. 2009
    ..Our findings suggest that vasopressin receptor antagonists could be of additional therapeutic value in the treatment of chronic proteinuric nephropathy...
  20. doi request reprint Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Stem Cells 28:513-22. 2010
    ..Altogether these results highlight the potential of human CB-MSCs as future cell therapy for testing in human AKI...
  21. pmc ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy
    Erica Rurali
    IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy
    Diabetes 62:3599-609. 2013
    ..Screening for Pro618Ala polymorphism may help identify patients with diabetes at highest risk who may benefit the most from early reno- and cardioprotective therapy. ..
  22. doi request reprint Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes
    Elena Gagliardini
    Mario Negri Institute for Pharmacological Research, University of Bergamo, Bergamo, Italy
    Am J Physiol Renal Physiol 297:F1448-56. 2009
    ..These findings provide mechanistic insights to explain the antiproteinuric effect of this combined therapy in diabetes...
  23. ncbi request reprint Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin
    Cristina Zanchi
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Immunol 181:1460-9. 2008
    ..coli O157:H7 infection...
  24. pmc In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 166:1309-20. 2005
    ..Increased ET-1 generation might alter glomerular permselectivity and amplify the noxious effect of protein overload on dysfunctional podocytes...
  25. pmc Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype
    Marina Noris
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Via Camozzi, 3 24020 Ranica Bg, Italy
    Clin J Am Soc Nephrol 5:1844-59. 2010
    ..Most childhood cases are caused by Shiga toxin-producing bacteria. The other form, atypical HUS (aHUS), accounts for 10% of cases and has a poor prognosis. Genetic complement abnormalities have been found in aHUS...
  26. doi request reprint Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat
    Anna Pezzotta
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Ranica, Bergamo, Italy
    Transplantation 85:1476-82. 2008
    ..T cell stimulation by alloantigens is followed by cell cycle progression, an event that is critically dependent on cyclin-dependent kinases...
  27. doi request reprint Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Km Rosso, Via Stezzano, 87 24126 Bergamo, Italy
    Am J Physiol Renal Physiol 303:F1370-81. 2012
    ....
  28. ncbi request reprint Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Arthritis Rheum 56:1629-37. 2007
    ..To examine whether the cyclin-dependent kinase (CDK) inhibitor seliciclib ameliorates autoimmune nephritis in (NZB x NZW)F(1) mice...
  29. ncbi request reprint Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells
    Susanna Tomasoni
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplantation 79:1056-61. 2005
    ....
  30. doi request reprint Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Km Rosso, Via Stezzano, 87, 24126 Bergamo, Italy
    Am J Physiol Renal Physiol 299:F1203-11. 2010
    ..These data suggest a strategy to target proteinuria to try to achieve regression of renal disease in diabetic patients who do not fully benefit from RAS inhibition alone...
  31. pmc Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
    Jessica Caprioli
    Mario Negri Institute for Pharmacologic Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Bergamo, Italy
    Blood 108:1267-79. 2006
    ..Hopefully this will translate into improved management and therapy of patients and will provide the way to design tailored treatments...
  32. ncbi request reprint Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial
    Giuseppe Remuzzi
    Department of Renal Medicine, Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 18:1973-85. 2007
    ..In view of the cost, standard immunosuppression regimens for kidney transplantation should perhaps include azathioprine rather than MMF...
  33. doi request reprint Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury
    Paola Cassis
    Transplant Research Center, Chiara Cucchi De Alessandri and Gilberto Crespi Mario Negri Institute for Pharmacological Research, Ranica, Bergamo, Italy
    Kidney Int 81:903-18. 2012
    ..Thus non-erythropoietic derivatives of EPO may be useful to prevent chronic renal allograft injury...
  34. ncbi request reprint DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic properties
    Sistiana Aiello
    Transplant Research Center, Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplantation 83:474-84. 2007
    ..Here we investigate the potency, the phenotype, and the mechanism of action of dnIKK2-DC-induced regulatory cells and we evaluated their tolerogenic properties in vivo...
  35. pmc Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis
    Mauro Abbate
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 161:2179-93. 2002
    ..Agents to reduce TGF-beta1, possibly combined with angiotensin blockade, should have priority in novel approaches to treatment of progressive nephropathies...
  36. ncbi request reprint Regulatory T cells and T cell depletion: role of immunosuppressive drugs
    Marina Noris
    Department of Immunology and Organ Transplantation, Ospedali Riuniti Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 18:1007-18. 2007
    ..These findings will be instrumental in developing "tolerance permissive" immunosuppressive regimens in the clinical setting...
  37. pmc Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 169:1965-75. 2006
    ..These data suggest that the podocyte is a target of Stx, a novel stimulus for the synthesis of ET-1, which may control cytoskeleton remodeling and glomerular permeability in an autocrine fashion...
  38. ncbi request reprint Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury
    Piero Ruggenenti
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Bergamo, Italy
    Transplantation 84:956-64. 2007
    ..This might translate into more effective protection against chronic graft injury compared to cyclosporin A (CsA), which, in the same clinical setting, does not affect Treg...
  39. ncbi request reprint Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies
    Ruth Campbell
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 63:1094-103. 2003
    ..Proteinuria predicts renal disease progression, and its reduction by angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor antagonists (ARA) is renoprotective...
  40. doi request reprint Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo, Italy
    Am J Physiol Renal Physiol 304:F808-19. 2013
    ..Altogether these data raise serious concerns on the use of bardoxolone analogs in Type 2 diabetic nephropathy...
  41. doi request reprint Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells
    Simona Buelli
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 75:1050-9. 2009
    ..Thus, protein overload reduces the ability of the tubule cell to bind factor H and counteract complement activation, effects instrumental to renal disease progression...
  42. ncbi request reprint Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Nephron Exp Nephrol 104:e158-68. 2006
    ..We investigated whether in a two-kidney diabetic model the time at which treatment started predicted the response to TGFbeta antagonist...
  43. ncbi request reprint Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 66:1959-65. 2004
    ....
  44. ncbi request reprint Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice
    Marina Morigi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Stem Cells 26:2075-82. 2008
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  45. doi request reprint The Toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts
    Marina Noris
    Transplant Research Center Chiara Cucchi De Alessandri and Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Via Camozzi 3, 24020 Ranica, Bergamo, Italy
    J Immunol 183:4249-60. 2009
    ..Thus, TIR8 acts locally as a key regulator of allogeneic immune response in the kidney. Tir8 expression and/or signaling in donor tissue are envisaged as a novel target for control of innate immunity and amelioration of graft survival...
  46. doi request reprint The GFR and GFR decline cannot be accurately estimated in type 2 diabetics
    Flavio Gaspari
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 84:164-73. 2013
    ..Thus, our study questions the use of any estimation formula to identify hyperfiltering patients and monitor renal disease progression and response to treatment in type 2 diabetics without overt nephropathy. ..
  47. doi request reprint Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation
    Norberto Perico
    Department of Immunology and Transplantation, Azienda Ospedaliera IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy
    Transpl Int 26:867-78. 2013
    ..Induction therapy without basiliximab does not offer any advantage on CD4(+) FoxP3(+) Treg expansion (ClinicalTrials.gov number: NCT 00752479)...
  48. ncbi request reprint Preventing microalbuminuria in type 2 diabetes
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi, Ranica, Bergamo, Italy
    N Engl J Med 351:1941-51. 2004
    ....
  49. ncbi request reprint Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, 11 24125 Bergamo, Italy
    J Am Soc Nephrol 17:1665-72. 2006
    ....
  50. ncbi request reprint Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings
    Eliana Gotti
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Italy
    J Am Soc Nephrol 14:755-66. 2003
    ..CsA reduction did not adversely affect histology. Per-protocol biopsy more than 1 yr after kidney transplantation is a safe procedure to guide change of drug regimen and to lower the risk of major side effects...
  51. pmc Sirolimus therapy to halt the progression of ADPKD
    Norberto Perico
    Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 21:1031-40. 2010
    ..In summary, sirolimus halted cyst growth and increased parenchymal volume in patients with ADPKD. Whether these effects translate into improved long-term outcomes requires further investigation...
  52. pmc Disruption of the Ang II type 1 receptor promotes longevity in mice
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, Bergamo, Italy
    J Clin Invest 119:524-30. 2009
    ....
  53. pmc Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition
    Daniela Macconi
    Mario Negri Institute for Pharmacological Research, Department of Biomedical Engineering, Laboratory of Renal Biophysics, Via Gavazzeni, 11, 24125 Bergamo, Italy
    Am J Pathol 174:797-807. 2009
    ..Increased parietal podocyte number in lisinopril-treated MWF rats suggests that the remodeling of Bowman's capsule epithelial cells contributes to this effect...
  54. pmc Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 5:1928-38. 2010
    ....
  55. ncbi request reprint Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Bergamo, Italy
    Kidney Int 65:2193-200. 2004
    ..Here we addressed the role of nephrin, CD2-associated protein (CD2AP), and podocin together with the integrity of the slit diaphragm in the pathogenesis of proteinuria of patients with diabetes and nephropathy...
  56. pmc Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases, Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 31:1629-34. 2008
    ..We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH)...
  57. pmc Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 3:1652-9. 2008
    ..Whether this is associated with kidney function restoration and regression of the glomerular pathology was evaluated...
  58. doi request reprint Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation
    Nadia Azzollini
    Department of Immunology and Organ Transplantation, Ospedali Riuniti Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Kidney Int 74:1420-8. 2008
    ..The efficacy of propionyl-L-carnitine to modulate ischemia-reperfusion injury during transplantation suggests that its use in human transplantation is worth testing...
  59. ncbi request reprint Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Lancet 365:939-46. 2005
    ....
  60. ncbi request reprint The RAAS in the pathogenesis and treatment of diabetic nephropathy
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Nat Rev Nephrol 6:319-30. 2010
    ..Such findings will have major implications, particularly in settings where money and facilities are limited and in settings where renal replacement therapy is not available and the prevention of kidney failure is life saving...
  61. doi request reprint Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats
    Paola Cassis
    Transplant Research Center, Chiara Cucchi De Alessandri and Gilberto Crespi Mario Negri Institute for Pharmacological Research, Via Camozzi, Bergamo, Italy
    Transplantation 92:271-9. 2011
    ..Moreover, prolonged cold ischemia is a predictor of long-term graft loss in kidney transplant patients...
  62. pmc Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility
    Norberto Perico
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Department of Immunology and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Parco Scientifico Tecnologico Kilometro Rosso, via Stezzano 87, 24126 Bergamo, Italy
    Clin J Am Soc Nephrol 6:412-22. 2011
    ..Mesenchymal stromal cells (MSCs) abrogate alloimmune response in vitro, suggesting a novel cell-based approach in transplantation. Moving this concept toward clinical application in organ transplantation should be critically assessed...
  63. ncbi request reprint Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement
    Marina Noris
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases, Aldo e Cele Daccò, Villa Camozzi Ranica, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 16:1177-83. 2005
    ..In addition, a heterozygous mutation (causing an S890I change) in factor H of complement was found in the patient who developed chronic renal failure but not in her sister, who presented with exclusive neurologic symptoms...
  64. pmc Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention
    Daniela Macconi
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Am J Pathol 168:1073-85. 2006
    ..These data demonstrate that strategies aimed at stabilizing podocyte-podocyte contacts and targeting the relevant intracellular signal transduction are crucial to renoprotection...
  65. ncbi request reprint Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Am Soc Nephrol 17:3472-81. 2006
    ..As compared with trandolapril, Veratran may help with achievement of target BP with less need for concomitant antihypertensive medications...
  66. ncbi request reprint Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells
    Regiane Aparecida Cavinato
    Transplant Research Center, Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Transplantation 79:1034-9. 2005
    ..It was suggested that maintenance of tolerance to organ transplantation may depend on the formation of T regulatory cells...
  67. ncbi request reprint Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat
    Ariela Benigni
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 14:1816-24. 2003
    ....
  68. ncbi request reprint Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Villa Camozzi, Ranica, Italy
    J Hypertens 29:207-16. 2011
    ..To address whether nondihydropyridine calcium-channel blocker added-on angiotensin-converting-enzyme inhibitor therapy ameliorates albuminuria and cardiovascular outcomes in type 2 diabetes patients...
  69. ncbi request reprint How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach
    Carla Zoja
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 13:2898-908. 2002
    ..These data suggest a possible future strategy to induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients who do not fully respond to ACEi therapy...
  70. pmc Glomerular hyperfiltration and renal disease progression in type 2 diabetes
    Piero Ruggenenti
    Clinical Research Center for Rare Diseases Aldo and Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 35:2061-8. 2012
    ..To describe the prevalence and determinants of hyperfiltration (glomerular filtration rate [GFR] ≥120 mL/min/1.73 m(2)), GFR decline, and nephropathy onset or progression in type 2 diabetic patients with normo- or microalbuminuria...
  71. doi request reprint Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model
    Fabio Sangalli
    Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Physiol Renal Physiol 300:F1291-300. 2011
    ..They also suggest that evaluation of tubular protein concentration levels could help to identify patients at risk of kidney disease progression and to improve clinical management...
  72. ncbi request reprint Kidney failure stabilizes after an increase over 2 decades
    Paolo Cravedi
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Ren Care 33:100-4. 2007
    ..Early intervention may be important to maximize renoprotection, especially in diabetics...
  73. ncbi request reprint Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation
    Daniela Corna
    Mario Negri Institute for Pharmacological Research, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Am J Nephrol 27:630-8. 2007
    ..However, some safety concerns have been recently raised on the use of these agents, mainly due to transient episodes of proteinuria observed in patients receiving high doses of rosuvastatin...
  74. ncbi request reprint Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors
    Dario Cattaneo
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    J Ren Nutr 15:71-6. 2005
    ..Preliminary studies have shown that a multidrug approach may induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients whose condition does not fully respond to a single treatment...
  75. ncbi request reprint Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies
    Piero Ruggenenti
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Italy
    Clin J Am Soc Nephrol 3:1511-25. 2008
    ....
  76. ncbi request reprint Chronic nephropathies: individual risk for progression to end-stage renal failure as predicted by an integrated probabilistic model
    Borislav D Dimitrov
    Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Nephron Clin Pract 95:c47-59. 2003
    ..To predict risk of end-stage renal disease (ESRD) in individual patients with chronic nephropathy...
  77. ncbi request reprint Insulin-like growth factor-1 sustains stem cell mediated renal repair
    Barbara Imberti
    Mario Negri Institute for Pharmacological Research, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Am Soc Nephrol 18:2921-8. 2007
    ..These findings indicate that MSC exert beneficial effects on tubular cell repair in acute kidney injury by producing the mitogenic and pro-survival factor IGF-1...
  78. ncbi request reprint The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises
    Arrigo Schieppati
    Department of Medicine and Transplantation, Azienda Ospedaliera Ospedali Riuniti, Bergamo, Italy
    Kidney Int 64:1947-55. 2003
  79. ncbi request reprint Does remission of renal disease associated with antihypertensive treatment exist?
    Paolo Cravedi
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, Bergamo, Italy
    Curr Hypertens Rep 9:160-5. 2007
    ..Early intervention, before progressive glomerulosclerosis and scarring is initiated by increased protein traffic, may be important to maximize reno- and cardioprotection, especially in diabetes...
  80. ncbi request reprint Timed urine collections are not needed to measure urine protein excretion in clinical practice
    Flavio Gaspari
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Am J Kidney Dis 47:1-7. 2006
  81. ncbi request reprint Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade
    Aneliya Parvanova
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Villa Camozzi, Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Expert Opin Pharmacother 6:1931-42. 2005
    ..Whether this also applies to diabetic nephropathy and related cardiovascular outcomes is still unknown...
  82. ncbi request reprint Clinical practice. Nephropathy in patients with type 2 diabetes
    Giuseppe Remuzzi
    Unit of Nephrology, Ospedali Riuniti di Bergamo, Italy
    N Engl J Med 346:1145-51. 2002
  83. ncbi request reprint Proteinuria in diabetic nephropathy: treatment and evolution
    Ruth C Campbell
    Division of Nephrology and Dialysis, Ospedali Riuniti di Bergamo and Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11, Bergamo 24125, Italy
    Curr Diab Rep 3:497-504. 2003
    ..Screening and implementation of these strategies is needed to reverse the epidemic of diabetic renal disease...
  84. doi request reprint Angiotensin receptors as determinants of life span
    Paola Cassis
    Mario Negri Institute for Pharmacological Research, Via Gavazzeni, 11, 24125 Bergamo, Italy
    Pflugers Arch 459:325-32. 2010
    ....
  85. pmc Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination
    Sanjib Kumar Sharma
    Clinical Research Centre for Rare Diseases Aldo e Cele Dacco, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Italy
    Vasc Health Risk Manag 3:453-65. 2007
    ..Thus, trandolapril/verapamil is an effective option for treatment of hypertensive diabetes patients requiring more than one agent to achieve target blood pressure...
  86. ncbi request reprint Favorable effect of cotransfection with TGF-beta and CTLA4Ig of the donor kidney on allograft survival
    Susanna Tomasoni
    Mario Negri Institute for Pharmacological Research, Institute for Pharmacological Research, Bergamo, Italy
    Am J Nephrol 24:275-83. 2004
    ..Since we previously demonstrated that transfection of the donor kidney with CTLA4Ig significantly prolonged allograft survival, we also evaluated the effect of a combined injection of AdvIL-10 or AdTGF-beta3 with the AdCTLA4Ig...
  87. ncbi request reprint Latest treatment strategies for membranous nephropathy
    Piero Ruggenenti
    Mario Negri Institute for Pharmacological Research, Department of Renal Medicine, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Via Gavazzeni 11, 24125 Bergamo, Italy
    Expert Opin Pharmacother 8:3159-71. 2007
    ..This paper reviews the safety/efficacy profile of various agents that have been proposed as therapy for this disease, with particular focus on the latest, more specific and hypothesis-driven approaches...
  88. ncbi request reprint Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinase-dependent pathways
    Roberta Donadelli
    Mario Negri Institute for Pharmacological Research and Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Am Soc Nephrol 14:2436-46. 2003
    ..Fractalkine might contribute to direct mononuclear cells into peritubular interstitium and enhance their adhesion property, which in turn would favor inflammation and disease progression...
  89. ncbi request reprint Rituximab in idiopathic membranous nephropathy: a one-year prospective study
    Piero Ruggenenti
    Aldo and Cele Daccò Clinical Research Center for Rare Diseases and Negri Bergamo Laboratories, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    J Am Soc Nephrol 14:1851-7. 2003
    ..The long-term risk/benefit profile of this novel, disease-specific approach seems much more favorable to that of commonly employed immunosuppressive drugs...
  90. ncbi request reprint Intensified inhibition of renin-angiotensin system: a way to improve renal protection?
    Paolo Cravedi
    Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Via Gavazzeni, 11 24125 Bergamo, Italy
    Curr Hypertens Rep 9:430-6. 2007
    ....
  91. ncbi request reprint Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease
    Jessica Caprioli
    Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Villa Camozzi, Via Camozzi 3, 24020 Ranica, Italy
    Hum Mol Genet 12:3385-95. 2003
    ..In conclusion HF1 mutations are frequent in patients with D-HUS (24%). Common polymorphisms of HF1 may contribute to D-HUS manifestation in subjects with and without HF1 mutations...
  92. doi request reprint Hepatitis C infection and chronic renal diseases
    Norberto Perico
    Department of Medicine and Transplantation Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Clin J Am Soc Nephrol 4:207-20. 2009
    ....
  93. ncbi request reprint Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation
    Dario Cattaneo
    Department of Immunology, Ospedali Riuniti di Bergamo, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Kidney Int 62:1060-7. 2002
    ..The impact of steroids on MPA pharmacokinetics, however, has not been investigated to date...
  94. doi request reprint Aldosterone and progression of kidney disease
    Monica Cortinovis
    Department of Medicine and Transplantation, Ospedali Riuniti di Bergamo Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Ther Adv Cardiovasc Dis 3:133-43. 2009
    ..Further studies in larger cohorts are now required to definitively address the safety and efficacy of aldosterone antagonism in patients with chronic kidney diseases...
  95. ncbi request reprint Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial
    Giuseppe Remuzzi
    Clinical Research Centre for Rare Diseases, Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Lancet 364:503-12. 2004
    ..We aimed to compare the antirejection activity of these two drugs with a new formulation of ciclosporin...
  96. ncbi request reprint Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion
    Daniela Cugini
    Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi Mario Negri Institute for Pharmacological Research, Villa Camozzi, Ranica, Bergamo, Italy
    Kidney Int 67:1753-61. 2005
    ..Ischemia/reperfusion (I/R) injury after organ transplantation is a major cause of delayed graft function. Following I/R, locally produced CXC chemokines attract and activate granulocytes, which in turn promote graft damage...
  97. ncbi request reprint The renin-angiotensin system in progression, remission and regression of chronic nephropathies
    Claudio Aros
    Mario Negri Institute for Pharmacological Research, Unit of Nephrology and Dialysis, Ospedali Riuniti di Bergamo, 24128 Bergamo, Italy
    J Hypertens Suppl 20:S45-53. 2002
    ..A multimodal approach aimed at reducing or abolishing all the risk factors for progression may shorten the time to remission for the majority of patients with proteinuric nephropathies...
  98. ncbi request reprint Effect of high dose ramipril with or without indomethacin on glomerular selectivity
    Roberto Pisoni
    Aldo and Cele Daccò Clinical Research Center for Rare Diseases, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy
    Kidney Int 62:1010-9. 2002
    ..Up-titration above conventional doses and combined therapy with other antiproteinuric agents may serve to achieve renoprotection in patients at risk of rapid disease progression...
  99. ncbi request reprint Hyperhomocysteinemia and increased risk of retinopathy: a cross-sectional, case-control study in patients with type 2 diabetes
    Aneliya Parvanova
    Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Mario Negri Institute for Pharmacological Research, Bergamo, Italy
    Diabetes Care 25:2361. 2002
  100. doi request reprint The diabetic CKD patient--a major cardiovascular challenge
    Irene M van der Meer
    Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Ren Care 36:34-46. 2010
    ..Those involved in the delivery of care to patients with diabetes and CKD need to be aware of these issues and should adopt an individualised approach to treatment...